← Back to screener

Design Therapeutics, Inc. DSGN

Rank #2067 · Nasdaq · $0.7B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
34.9
P/E
-13.5
P/B
2.40
ROE
-17.9%
Op. Margin
–%
Debt Ratio
4%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -13.5x, P/B 2.40x. Ranks in the top 63% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -17.9%. Ranks in the top 81% of the universe.

Safety ★★★★★
Excellent

Debt ratio 4%. Ranks in the top 8% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021$0.0B$-0.0B$-0.0B$-0.0B-3685.8-68
2022–$-0.0B$-0.0B$-0.0B–-74
2023–$-0.1B$-0.1B$0.4B–4
2024$0.0B$-0.1B$-0.1B$0.3B–4
2025$0.0B$-0.1B$-0.0B$0.3B–4

← See the full screener